Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Longitudinal Assessment of Circulating Tumor Cells and Outcome in Small Cell Lung Cancer: A Sub-Study of RASTEN-A Randomized Trial with Low Molecular Weight Heparin
Lund Univ, Dept Clin Sci, Div Oncol, Barngatan 4, SE-22185 Lund, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration. Uppsala University, Science for Life Laboratory, SciLifeLab. Lund Univ, Dept Clin Sci, Div Oncol, Barngatan 4, SE-22185 Lund, Sweden.;Skane Univ Hosp, Dept Hematol Radiophys & Oncol, Lasarettsgatan 23A, SE-22185 Lund, Sweden.ORCID iD: 0000-0003-1585-5434
Lund Univ, Dept Clin Sci, Div Oncol, Barngatan 4, SE-22185 Lund, Sweden.;Lund Univ Hosp, Dept Resp Med, Entregatan 7, SE-22185 Lund, Sweden.
2023 (English)In: Cancers, ISSN 2072-6694, Vol. 15, no 12, article id 3176Article in journal (Refereed) Published
Abstract [en]

Simple Summary Small cell lung cancer (SCLC) is an aggressive lung cancer subtype associated with an overall poor prognosis but a variable response rate to chemotherapy. The measurement of circulating tumor cells (CTCs) offers a non-invasive method to monitor the disease and may provide prognostic information as potential guidance to clinicians in the management of SCLC. However, the value of CTCs during and after chemotherapy appears inconclusive. Here, we show that the detection of CTCs at baseline correlates to overall survival in SCLC, and that persistently detectable CTCs after completion of treatment adds further prognostic value. This suggests that repetitive analysis of CTCs during and after the course of treatment may have a role in the management of SCLC, warranting further studies. Circulating tumor cells (CTCs) may provide a liquid biopsy approach to disease monitoring in small cell lung cancer (SCLC), a particularly aggressive tumor subtype. Yet, the prognostic role of CTCs during and after treatment in relation to baseline remains ill-defined. Here, we assessed the value of longitudinal CTC analysis and the potential of low-molecular-weight heparin (LMWH) to reduce CTC abundance in SCLC patients from a randomized trial (RASTEN). Blood samples were collected at baseline, before chemotherapy Cycle 3, and at 2-month follow-up from 42 patients in total, and CTCs were quantified using the FDA-approved CellSearch system. We found a gradual decline in CTC count during and after treatment, independently of the addition of LMWH to standard therapy. Detectable CTCs at baseline correlated significantly to reduced survival compared to undetectable CTCs (unadjusted hazard ratio (HR) of 2.75 (95% CI 1.05-7.20; p = 0.040)). Furthermore, a persistent CTC count at 2-month follow-up was associated with a HR of 4.22 (95% CI 1.20-14.91; p = 0.025). Our findings indicate that persistently detectable CTCs during and after completion of therapy offer further prognostic information in addition to baseline CTC, suggesting a role for CTC in the individualized management of SCLC.

Place, publisher, year, edition, pages
MDPI, 2023. Vol. 15, no 12, article id 3176
Keywords [en]
small cell lung cancer, liquid biopsy, circulating tumor cells, prognostic biomarker
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-508056DOI: 10.3390/cancers15123176ISI: 001014216200001PubMedID: 37370786OAI: oai:DiVA.org:uu-508056DiVA, id: diva2:1783417
Available from: 2023-07-20 Created: 2023-07-20 Last updated: 2023-07-20Bibliographically approved

Open Access in DiVA

fulltext(1520 kB)59 downloads
File information
File name FULLTEXT01.pdfFile size 1520 kBChecksum SHA-512
b84ca40d294df380407c14f3d142db68fd6d3a43fecbff09226fa8d7ac1d8e1862281ff61a4225a708f46793522053ba0328ce11e5db14d10325c4511893208c
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records

Belting, Mattias

Search in DiVA

By author/editor
Belting, Mattias
By organisation
Neurooncology and neurodegenerationScience for Life Laboratory, SciLifeLab
In the same journal
Cancers
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 59 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 122 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf